AGEN - Celyad's Positive Data And Other News: The Good Bad And Ugly Of Biopharma
Celyad Reports Positive Update on Non Gene Edited Allogeneic CAR-T Therapy
Celyad (CYAD) announced update for its Phase 1 clinical trial alloSHRINK. The trial aims to assess the potential of its lead drug candidate CYAD-101 for patients suffering from metastatic colorectal cancer. It enrolled 15 patients with relapsed/refractory mCRC who progressed after chemo. Each patient was administered three consecutive doses of CYAD-101 concurrently with FOLFOX chemo.
The trial evaluated three consecutive dose levels of the drug candidate. The mean number of prior therapies received by patients enrolled in the trial were three and